P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance

[1]  C. Peixoto,et al.  New imidazolidine derivatives as anti-Trypanosoma cruzi agents: structure–activity relationships , 2012, Parasitology Research.

[2]  B. Hall,et al.  Benznidazole-Resistance in Trypanosoma cruzi Is a Readily Acquired Trait That Can Arise Independently in a Single Population , 2012, The Journal of infectious diseases.

[3]  A. Palmeira,et al.  Three decades of P-gp inhibitors: skimming through several generations and scaffolds. , 2012, Current medicinal chemistry.

[4]  L. Leon,et al.  Evaluation of thiosemicarbazones and semicarbazones as potential agents anti-Trypanosoma cruzi. , 2011, Experimental parasitology.

[5]  J. Cricco,et al.  The heme uptake process in Trypanosoma cruzi epimastigotes is inhibited by heme analogues and by inhibitors of ABC transporters. , 2011, Acta tropica.

[6]  S. Montgomery,et al.  Trypanosoma cruzi and Chagas' Disease in the United States , 2011, Clinical Microbiology Reviews.

[7]  A. Mejía-Jaramillo,et al.  Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to benznidazole in Trypanosoma cruzi , 2011, Parasites & Vectors.

[8]  M. Grever,et al.  Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells , 2011, The AAPS Journal.

[9]  L. Leon,et al.  Croton cajucara crude extract and isolated terpenes: activity on Trypanosoma cruzi , 2010, Parasitology Research.

[10]  G. Wilding,et al.  The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors , 2010, Cancer Chemotherapy and Pharmacology.

[11]  J. Sztajzel,et al.  Prevalence, Clinical Staging and Risk for Blood-Borne Transmission of Chagas Disease among Latin American Migrants in Geneva, Switzerland , 2010, PLoS neglected tropical diseases.

[12]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[13]  H. Morjani,et al.  Immunosuppressors as multidrug resistance reversal agents. , 2010, Methods in molecular biology.

[14]  J. Kolesar,et al.  A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 , 2010, Investigational New Drugs.

[15]  Xiankai Sun,et al.  Retention of the Radiotracers 64Cu-ATSM and 64Cu-PTSM in Human and Murine Tumors Is Influenced by MDR1 Protein Expression , 2009, Journal of Nuclear Medicine.

[16]  G. Sanz,et al.  Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). , 2009, Acta tropica.

[17]  R. Mortara,et al.  Characterization of a gene encoding alcohol dehydrogenase in benznidazole-susceptible and -resistant populations of Trypanosoma cruzi. , 2009, Acta tropica.

[18]  J. Ruiz,et al.  Molecular characterization of cytosolic and mitochondrial tryparedoxin peroxidase in Trypanosoma cruzi populations susceptible and resistant to benznidazole , 2009, Parasitology Research.

[19]  M. T. Bahia,et al.  Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection. , 2008, Experimental parasitology.

[20]  S. F. Fernández Villamil,et al.  Multiple NADPH-cytochrome P450 reductases from Trypanosoma cruzi suggested role on drug resistance. , 2008, Molecular and biochemical parasitology.

[21]  C. Carneiro,et al.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions , 2008, Parasitology Research.

[22]  A. Romanha,et al.  Proteomic analysis of Trypanosoma cruzi resistance to Benznidazole. , 2008, Journal of proteome research.

[23]  S. Goldenberg,et al.  Differential gene expression in Trypanosoma cruzi populations susceptible and resistant to benznidazole. , 2008, Acta tropica.

[24]  A. Ruiz,et al.  Anti-Trypanosoma cruzi effects of cyclosporin A derivatives: possible role of a P-glycoprotein and parasite cyclophilins , 2007, Parasitology.

[25]  D. Boykin,et al.  Cellular Effects of Reversed Amidines on Trypanosoma cruzi , 2007, Antimicrobial Agents and Chemotherapy.

[26]  D. Salmon,et al.  Heme requirement and intracellular trafficking in Trypanosoma cruzi epimastigotes. , 2007, Biochemical and biophysical research communications.

[27]  J. Castro,et al.  Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis) , 2006, Human & experimental toxicology.

[28]  S. Goldenberg,et al.  Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. , 2006, Molecular and biochemical parasitology.

[29]  M. Tibayrenc,et al.  Differential Gene Expression in Benznidazole-Resistant Trypanosoma cruzi Parasites , 2005, Antimicrobial Agents and Chemotherapy.

[30]  H. Gerhartz,et al.  Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914) , 2001, British journal of haematology.

[31]  A. Romanha,et al.  Drug resistance in Trypanosoma cruzi is not associated with amplification or overexpression of P-glycoprotein (PGP) genes. , 2001, Molecular and biochemical parasitology.

[32]  F. Opperdoes,et al.  Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania. , 2000, Molecular and biochemical parasitology.

[33]  S. Castanys,et al.  Characterization of a new ATP-binding cassette transporter in Trypanosoma cruzi associated to a L1Tc retrotransposon. , 1999, Biochimica et biophysica acta.

[34]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[35]  L. Travassos,et al.  Biosynthesis ofO-N-Acetylglucosamine-linked Glycans inTrypanosoma cruzi , 1998, The Journal of Biological Chemistry.

[36]  A. Romanha,et al.  In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole , 1998, Parasitology.

[37]  L. Travassos,et al.  Biosynthesis of O-N-acetylglucosamine-linked glycans in Trypanosoma cruzi. Characterization of the novel uridine diphospho-N-acetylglucosamine:polypeptide N-acetylglucosaminyltransferase-catalyzing formation of N-acetylglucosamine alpha1-->O-threonine. , 1998, The Journal of biological chemistry.

[38]  S. Ambudkar.  Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. , 1998, Methods in enzymology.

[39]  A. Sartorelli,et al.  Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. , 1997, Biochemical pharmacology.

[40]  A. Sartorelli,et al.  Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone. , 1997, Anticancer research.

[41]  M. J. Toledo,et al.  Trypanosoma cruzi: chemotherapy with benznidazole in mice inoculated with strains from Paraná state and from different endemic areas of Brazil. , 1997, Revista do Instituto de Medicina Tropical de Sao Paulo.

[42]  S. Castanys,et al.  Molecular characterization of a P-glycoprotein-related tcpgp2 gene in Trypanosoma cruzi. , 1996, Molecular and biochemical parasitology.

[43]  C. Larroque,et al.  Drug-resistant epimastigotes of Trypanosoma cruzi and persistence of this phenotype after differentiation into amastigotes. , 1995, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[44]  U. Lopes,et al.  Leishmania amazonensis: multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene. , 1995, Experimental parasitology.

[45]  J. Samuelson,et al.  Increase in mRNA of multiple Eh pgp genes encoding P-glycoprotein homologues in emetine-resistant Entamoeba histolytica parasites. , 1995, Gene.

[46]  G. A. Scarborough.  Drug-stimulated ATPase activity of the human P-glycoprotein , 1995, Journal of bioenergetics and biomembranes.

[47]  W. Dalton,et al.  P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. , 1995, Molecular aspects of medicine.

[48]  M. Ouellette,et al.  P-glycoprotein overexpression in methotrexate-resistant Leishmania tropica. , 1994, Biochemical pharmacology.

[49]  C. Wilson,et al.  Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. , 1993, Molecular and biochemical parasitology.

[50]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[51]  R. Neal,et al.  Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[52]  I. Pastan,et al.  ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[53]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[54]  S. G. Andrade,et al.  Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. , 1985, Bulletin of the World Health Organization.

[55]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[56]  C. Dolea,et al.  World Health Organization , 1949, International Organization.